Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Overview of attention for article published in Frontiers in Pharmacology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 22 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 14,956 followers.

RT @FrontPharmacol: New Research: Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leuke…

01 Mar 2023

Reply Repost Favourite

RT @gedefo_sefh: Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic…

10 Jan 2023

Reply Repost Favourite

Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis https://t.co/FFBwipBNTN

10 Jan 2023

Reply Repost Favourite

New Research: Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis https://t.co/NpcBYH2r35 #pharmacology

10 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.